• O-GlcNAcylation Rewires Glycolysis for Wnt-Driven Bone Forma

  2026-05-22

  This study uncovers how O-GlcNAcylation, a protein modification, is necessary for Wnt-stimulated bone formation by regulating aerobic glycolysis in osteoblasts. The findings reveal a metabolic mechanism linking Wnt signaling to bone anabolism, providing new avenues for skeletal and metabolic research.

• WP1066: Potent JAK2/STAT3 Inhibitor for Oncology and Regener

  2026-05-22

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor that blocks phosphorylation and downstream signaling, showing efficacy in renal cell carcinoma and acute myeloid leukemia models. Its activity extends to inhibition of tumor angiogenesis and modulation of macrophage-driven bone regeneration pathways.

• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-05-21

  0.4% Trypan Blue Solution provides researchers with a straightforward, membrane-integrity-based method for live/dead cell discrimination and viability measurement in cell culture workflows. It is not intended for diagnostic or medical applications, and its reliability depends on correct handling and appropriate assay context.

• Optogenetic Control of Gene Therapy Using Light-Inducible RN

  2026-05-21

  The referenced study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that enables precise, reversible gene expression in vivo via light exposure. This innovation provides a compact, allosteric switch for translational control, offering new possibilities for timed and tissue-specific therapeutic interventions, particularly for metabolic and retinal diseases.

• Deferasirox (SKU A8639): Reliable Iron Chelation in Cancer R

  2026-05-20

  This article provides scenario-driven guidance for using Deferasirox (SKU A8639), an oral iron chelator, in cell viability and cancer research assays. Drawing on recent literature and practical workflow insights, it addresses common laboratory challenges—including iron chelation specificity, protocol optimization, and vendor selection—to help researchers achieve reproducible, high-quality results.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-20

  This study reveals that IGF2BP3 stabilizes FZD1/7 mRNAs, enhancing cancer stem-like properties and resistance to carboplatin in triple-negative breast cancer (TNBC). The findings highlight a novel m6A-dependent regulatory mechanism, offering new targets to sensitize TNBC to platinum-based chemotherapy and improve treatment efficacy.

• AM 281: CB1 Cannabinoid Receptor Antagonist in TBI & Memory

  2026-05-19

  AM 281 stands out as a highly selective CB1 cannabinoid receptor antagonist for neuropharmacology, enabling precise modulation in cognitive dysfunction and traumatic brain injury models. Discover nuanced workflow strategies, troubleshooting insights, and direct applications informed by cutting-edge research on the CB1-CREB-GLT-1 axis.

• IMPDH-Dependent Nucleotide Metabolism Drives PEDV Replicatio

  2026-05-19

  The referenced study reveals how porcine epidemic diarrhea virus (PEDV) reprograms host guanine nucleotide metabolism to facilitate viral replication. Pharmacological inhibition or genetic knockdown of inosine monophosphate dehydrogenase (IMPDH) significantly impairs PEDV proliferation, highlighting IMPDH as a promising host-directed antiviral target.

• SIS3 Smad3 Inhibitor: Precision Control in Fibrosis Research

  2026-05-18

  SIS3 is a selective Smad3 inhibitor enabling targeted dissection of the TGF-β pathway in fibrosis, renal, and cancer models. This guide reveals practical workflows, troubleshooting insights, and experimental enhancements to maximize reproducibility and translational relevance using SIS3 from APExBIO.

• 7-Ethyl-10-hydroxycamptothecin: Mechanistic Insights & FUBP1

  2026-05-18

  Explore the dual mechanisms of 7-Ethyl-10-hydroxycamptothecin, a potent SN-38 analog, in advanced colon cancer research. This article delves into FUBP1 pathway inhibition and advanced protocol design, offering new scientific perspectives beyond standard apoptosis and cell cycle arrest workflows.

• Prednisone in Translational Research: Mechanisms, Models, an

  2026-05-17

  This thought-leadership article explores advanced mechanistic insights and actionable strategies for translational researchers using Prednisone, a synthetic corticosteroid, in immunology and neurodegeneration research. Bridging rigorous in vitro validation with strategic workflow optimization, we address the unique roles of Prednisone in cell cycle arrest, IL-2 pathway inhibition, and apoptosis induction in peripheral blood lymphocytes—contrasting its pharmaceutical rigor with the evolving standards of botanical research. Practical protocol parameters, competitive landscape analysis, and forward-looking guidance are provided for investigators seeking reproducibility and translational impact.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-05-16

  Clodronate Liposomes empower researchers to achieve selective, tissue-specific macrophage depletion in complex in vivo models, unlocking new insights into immune cell function and modulation. This article translates cutting-edge experimental workflows and troubleshooting strategies into actionable guidance for maximizing the impact of liposome-encapsulated clodronate in preclinical research.

• Live-Dead Cell Staining Kit: Transforming Cell Viability Ass

  2026-05-15

  The Live-Dead Cell Staining Kit leverages Calcein-AM and Propidium Iodide dual staining for robust, reproducible cell viability analysis in both microscopy and flow cytometry. Its precision and workflow integration surpass single-dye and exclusion methods, empowering translational research from drug cytotoxicity testing to advanced biomaterial evaluation.

• Strategic Cathepsin B Inhibition: Translational Leverage wit

  2026-05-15

  Explore the mechanistic and translational power of selective cathepsin B inhibition in cancer metastasis, neurodegeneration, and immunology. This thought-leadership piece details the evidence, strategic workflow integration, and unique advantages of CA-074 from APExBIO, contextualized by recent advances in necroptosis research.

• PP 1: Selective Src Family Tyrosine Kinase Inhibitor in Canc

  2026-05-14

  PP 1 is a potent and selective Src family tyrosine kinase inhibitor with nanomolar activity against Lck and Fyn, enabling precise modulation of cancer and immune signaling pathways. Its documented selectivity and robust in vitro and in vivo performance make it a critical tool for dissecting oncogenic mechanisms and evaluating immunotherapy strategies.

11363 records 1/758 page Next 12345 下5页 Last page